New drug cocktail shows promise for rare blood cancer
NCT ID NCT03623373
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of four drugs (acalabrutinib, bendamustine, rituximab, and cytarabine) as a first treatment for people with mantle cell lymphoma, a rare blood cancer. The goal was to see if this approach could safely improve remission rates before a stem cell transplant. The study included 13 adults aged 18 to 70 who were eligible for transplant. The results may help design larger trials to find a better standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib, bendamustine, rituximab, cytarabine
What this could lead to
If this combination works well, it could become a standard first treatment for mantle cell lymphoma, helping more patients achieve remission before a stem cell transplant.
What could go wrong
This was a very small pilot study with only 13 people. Larger studies are needed to confirm safety and effectiveness. The drugs can cause serious side effects like infections and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States